Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.

Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN.

PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007083. doi: 10.1371/journal.pntd.0007083. eCollection 2019 Feb. Review.

2.

Memory CD4+ T cells enhance B-cell responses to drifting influenza immunization.

Gage E, Van Hoeven N, Dubois Cauwelaert N, Larsen SE, Erasmus J, Orr MT, Coler RN.

Eur J Immunol. 2019 Feb;49(2):266-276. doi: 10.1002/eji.201847852. Epub 2018 Dec 21.

PMID:
30548475
3.

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP. No abstract available.

PMID:
30428263
4.

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN.

NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.

5.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team.

NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.

6.

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N.

Mol Ther. 2018 Oct 3;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.010. Epub 2018 Aug 2.

PMID:
30078765
7.

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Larsen SE, Baldwin SL, Orr MT, Reese VA, Pecor T, Granger B, Dubois Cauwelaert N, Podell BK, Coler RN.

Vaccines (Basel). 2018 May 24;6(2). pii: E30. doi: 10.3390/vaccines6020030.

8.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
9.

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN.

Front Immunol. 2018 Feb 19;9:295. doi: 10.3389/fimmu.2018.00295. eCollection 2018.

10.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.

NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

11.

Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Cecílio P, Pérez-Cabezas B, Fernández L, Moreno J, Carrillo E, Requena JM, Fichera E, Reed SG, Coler RN, Kamhawi S, Oliveira F, Valenzuela JG, Gradoni L, Glueck R, Gupta G, Cordeiro-da-Silva A.

PLoS Negl Trop Dis. 2017 Nov 27;11(11):e0005951. doi: 10.1371/journal.pntd.0005951. eCollection 2017 Nov.

12.

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

Allen JD, Owino SO, Carter DM, Crevar CJ, Reese VA, Fox CB, Coler RN, Reed SG, Baldwin SL, Ross TM.

Vaccine. 2017 Sep 12;35(38):5209-5216. doi: 10.1016/j.vaccine.2017.07.107. Epub 2017 Aug 5.

PMID:
28789850
13.

CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.

Christiaansen AF, Dixit UG, Coler RN, Marie Beckmann A, Reed SG, Winokur PL, Zimmerman MB, Varga SM, Wilson ME.

Vaccine. 2017 Jul 24;35(33):4255-4261. doi: 10.1016/j.vaccine.2017.06.013. Epub 2017 Jun 27.

14.

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D.

Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426.

15.

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.

Clin Transl Immunology. 2016 Nov 2;5(11):e108. eCollection 2016 Nov.

16.

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Dubois Cauwelaert N, Baldwin SL, Orr MT, Desbien AL, Gage E, Hofmeyer KA, Coler RN.

Eur J Immunol. 2016 Dec;46(12):2719-2729. doi: 10.1002/eji.201646399. Epub 2016 Nov 9.

17.

Translational Activities to Enable NTD Vaccines.

Gray SA, Coler RN, Carter D, Siddiqui AA.

Prog Mol Biol Transl Sci. 2016;142:291-315. doi: 10.1016/bs.pmbts.2016.05.004. Epub 2016 Jul 9. Review.

PMID:
27571699
18.

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.

Hofmeyer KA, Duthie MS, Laurance JD, Favila MA, Van Hoeven N, Coler RN, Reed SG.

Clin Vaccine Immunol. 2016 Sep 6;23(9):785-94. doi: 10.1128/CVI.00251-16. Print 2016 Sep.

19.

Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis.

Ghosh P, Bhaskar KR, Hossain F, Khan MA, Vallur AC, Duthie MS, Hamano S, Salam MA, Huda MM, Khan MG, Coler RN, Reed SG, Mondal D.

Parasit Vectors. 2016 Jul 4;9(1):383. doi: 10.1186/s13071-016-1667-2.

20.

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.

Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG.

Vaccine. 2016 May 27;34(25):2779-86. doi: 10.1016/j.vaccine.2016.04.067. Epub 2016 May 1.

21.

Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.

Cha SB, Kim WS, Kim JS, Kim H, Kwon KW, Han SJ, Cho SN, Coler RN, Reed SG, Shin SJ.

Vaccine. 2016 Apr 27;34(19):2179-87. doi: 10.1016/j.vaccine.2016.03.029. Epub 2016 Mar 20.

PMID:
27005808
22.

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.

Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN.

PLoS One. 2016 Feb 22;11(2):e0149610. doi: 10.1371/journal.pone.0149610. eCollection 2016.

23.

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D'Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM.

Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.

24.

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.

Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT.

PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. eCollection 2016.

25.

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Baldwin SL, Reese VA, Huang PW, Beebe EA, Podell BK, Reed SG, Coler RN.

Clin Vaccine Immunol. 2015 Dec 9;23(2):137-47. doi: 10.1128/CVI.00458-15. Print 2016 Feb.

26.

Leishmania vaccine development: exploiting the host-vector-parasite interface.

Reed SG, Coler RN, Mondal D, Kamhawi S, Valenzuela JG.

Expert Rev Vaccines. 2016;15(1):81-90. doi: 10.1586/14760584.2016.1105135. Epub 2015 Nov 23. Review.

27.

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults.

Santini-Oliveira M, Coler RN, Parra J, Veloso V, Jayashankar L, Pinto PM, Ciol MA, Bergquist R, Reed SG, Tendler M.

Vaccine. 2016 Jan 20;34(4):586-594. doi: 10.1016/j.vaccine.2015.10.027. Epub 2015 Nov 10.

PMID:
26571311
28.

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

Orr MT, Beebe EA, Hudson TE, Argilla D, Huang PW, Reese VA, Fox CB, Reed SG, Coler RN.

Vaccine. 2015 Nov 27;33(48):6570-8. doi: 10.1016/j.vaccine.2015.10.115. Epub 2015 Nov 3.

29.

Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT.

J Immunol. 2015 Oct 1;195(7):3190-7. doi: 10.4049/jimmunol.1501118. Epub 2015 Aug 21.

30.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

31.

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Orr MT, Windish HP, Beebe EA, Argilla D, Huang PW, Reese VA, Reed SG, Coler RN.

J Infect Dis. 2015 Aug 1;212(3):495-504. doi: 10.1093/infdis/jiv055. Epub 2015 Jan 30.

32.

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.

Orr MT, Ireton GC, Beebe EA, Huang PW, Reese VA, Argilla D, Coler RN, Reed SG.

J Immunol. 2014 Sep 15;193(6):2911-8. doi: 10.4049/jimmunol.1401103. Epub 2014 Aug 1.

33.

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Baldwin SL, Reese V, Granger B, Orr MT, Ireton GC, Coler RN, Reed SG.

Clin Vaccine Immunol. 2014 Sep;21(9):1309-13. doi: 10.1128/CVI.00372-14. Epub 2014 Jul 16.

34.

Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Duthie MS, Coler RN, Laurance JD, Sampaio LH, Oliveira RM, Sousa AL, Stefani MM, Maeda Y, Matsuoka M, Makino M, Reed SG.

Infect Immun. 2014 Sep;82(9):3979-85. doi: 10.1128/IAI.02145-14. Epub 2014 Jul 14.

35.

Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.

Fox CB, Mulligan SK, Sung J, Dowling QM, Fung HW, Vedvick TS, Coler RN.

Int J Nanomedicine. 2014 Mar 11;9:1367-77. doi: 10.2147/IJN.S56582. eCollection 2014.

36.

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN.

PLoS One. 2014 Jan 3;9(1):e83884. doi: 10.1371/journal.pone.0083884. eCollection 2014.

37.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

38.

Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2014 Mar;94(2):140-7. doi: 10.1016/j.tube.2013.08.010. Epub 2013 Sep 7.

39.

Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis.

Vallur AC, Duthie MS, Reinhart C, Tutterrow Y, Hamano S, Bhaskar KR, Coler RN, Mondal D, Reed SG.

Clin Microbiol Infect. 2014 Jun;20(6):O374-83. doi: 10.1111/1469-0691.12421. Epub 2013 Nov 18.

40.

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.

Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG.

Vaccine. 2013 Dec 2;31(49):5848-55. doi: 10.1016/j.vaccine.2013.09.069. Epub 2013 Oct 10.

PMID:
24120675
41.

Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Jones GJ, Steinbach S, Clifford D, Baldwin SL, Ireton GC, Coler RN, Reed SG, Vordermeier HM.

Vaccine. 2013 Oct 25;31(45):5250-5. doi: 10.1016/j.vaccine.2013.08.051. Epub 2013 Sep 5.

42.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN.

J Control Release. 2013 Nov 28;172(1):190-200. doi: 10.1016/j.jconrel.2013.07.030. Epub 2013 Aug 9.

43.

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.

44.

Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.

McElhaney JE, Coler RN, Baldwin SL.

Expert Rev Vaccines. 2013 Jul;12(7):759-66. doi: 10.1586/14760584.2013.811193. Review.

PMID:
23885821
45.

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O'Donnell J, Desbien AL, Reed SG, Coler RN.

Eur J Immunol. 2013 Sep;43(9):2398-408. doi: 10.1002/eji.201243124. Epub 2013 Jul 3.

46.

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL.

Influenza Other Respir Viruses. 2013 Sep;7(5):815-26. doi: 10.1111/irv.12031. Epub 2012 Nov 5.

47.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.

48.

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ.

PLoS One. 2012;7(7):e41144. doi: 10.1371/journal.pone.0041144. Epub 2012 Jul 19.

49.

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN.

J Immunol. 2012 Mar 1;188(5):2189-97. doi: 10.4049/jimmunol.1102696. Epub 2012 Jan 30.

50.

Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Ching LK, Mompoint F, Guderian JA, Picone A, Orme IM, Coler RN, Reed SG, Baldwin SL.

J Immunol Methods. 2011 Oct 28;373(1-2):54-62. doi: 10.1016/j.jim.2011.07.021. Epub 2011 Aug 3.

Supplemental Content

Loading ...
Support Center